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Background: Glioblastoma multiforme (GBM) accounts 
for approximately 20% of primary adult-brain neoplasms 
and has a poor prognosis; life expectancy is 12 months or 
less after diagnosis. Temozolomide (TMZ) has become 
the standard therapy for GBM, combined with surgery 
and radiochemotherapy. Evaluation is important due to 
its association with the continuity or termination of 
therapy. Several studies have aimed to improve the 
measurement of the therapy response of GBM. The 
Response Assessment in Neuro-Oncology (RANO) criteria, 
published in 2010, has become a widely used tool for 
evaluating TMZ response in patients with GBM. These 
criteria combine clinical manifestation, steroid therapy, 
and brain magnetic resonance imaging (MRI). 
Case: We report two GBM cases with standard 
management of two female patients of reproductive age 
and with specific clinical manifestations diagnosed with 
 
GBM in their left temporal lobes. A 24-year-old 
woman showed a complete response, and a 41-
year-old woman showed a progressive response. 
Discussion: We analyzed the TMZ responses for 
the two cases based on the RANO criteria. 
Prognostic factors that differentiate TMZ 
response in GBM include age, the Karnofsky 
Performance Status (KPS), the extension of 
surgery, presence of comorbidities, and 
intratumoral hemorrhage seen on MRI. 
Conclusion: The differences in temozolomide 
response between two patients based on the 
RANO criteria are related to the presence of 
comorbidities, intratumoral hemorrhage seen on 
MRI, and surgery at initial diagnosis. 
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 Background 
According to the World Health Organization (WHO) 
classification (2016), glioblastoma multiforme 
(GBM) is an astrocytoma grade IV tumor of the 
central nervous system. About 90% of GBM cases 
are primary gliomas arising from normal glial cells, 
while the remaining 10% are secondary gliomas 
originating from lower-grade tumors.1 This tumor 
accounts for approximately 20% of all adult brain 
tumors and is the second-largest type of tumor 
after meningioma.2 Epidemiological data show that 
GBM cases in Europe and America are affected 2-–
3 adults per 100,000 adults each year, with an 
incidence rate of men versus women is of 1.26:1.1 
Life expectancy time is generally less than 12 
months after diagnosis.3 
The combination of surgery, radiation, and 
treatment with temozolomide (TMZ) has become 
the standard therapy for GBM.3,4 Temozolomide is 
also used in groups of recurrent GBM cases as a 
monotherapy or combination with other 
regimens.5 A phase III RCT study by the European 
Organization for Research and Treatment of 
Cancer (EORTC) and the National Cancer Institute 
of Canada  – Clinical Trials Group (NCIC CTG) 
reported an increase in median time and life 
expectancy of 2 years in GBM patients treated with 
concomitant radiochemotherapy followed by 
adjuvant TMZ alone.6  
The evaluation of therapy in GBM is important 
because it is associated with the continuation or 
termination of treatment. Research has been 
improving the ability to provide measurable 
evaluations in GBM management. In phase II and 
III trials, a study by Chinot et al. demonstrated 
significant measurable efficacy of therapy in GBM 
patients including clinical outcome, radiological 
response, and tumor-control duration (such as 
progression-free survival).7 One of the major tools 
for the assessment of treatment response in GBM 
cases is the RANO (Response Assessment in Neuro-
Oncology) criteria introduced in 2010, replacing 
the MacDonald criteria (1990).7 These criteria use 
magnetic resonance imaging (MRI) features, 
clinical conditions, and steroid use as the basis for 
a therapeutic response. The authors reported two 
GBM cases with standard management and 





A 24-year-old woman, Mrs. N, presented with a 
major complaint of headache on the left side that 
had worsened over a month, blurred vision in the 
left eye, and projectile vomiting. No seizures, 
hemifacial spasms, loss of speech, hemiparesis, 
half-body thick sensation, fever, or history of head 
trauma were reported. The patient was found to 
be compos mentis with no meningeal signs. Focal 
neurologic deficits were found in the form of 
bilateral papilledema, right facial paresis, and mild 
central-right lingual paresis, as well as mild right 
hemiparesis.  
Neuroradiologic imaging of the head using contrast 
MRI showed supratentorial cystic lesion, contrast-
enhanced in the left temporal region, of 
4.81x4.73x4.5 cm, accompanied by perifocal 
edema, a midline shift to the right as far as 0.95 cm 
and the magnetic resonance spectroscopy showed 
an increase in the choline to creatinine ratio. Those 
tended to be high-grade malignant cystic 
astrocytoma. The patient’s KPS improved following 
surgery (from a score of 60 to 90). Histological 
examination demonstrated oval, heavy 
pleomorphism with multinucleated giant cell and 
blood vessel proliferation, mitosis, bleeding, and 















Figure 1. Initial imaging of contrast head MRI  
(a) T1-weighted sequence, (b) T2-weighted 
sequence, (c) DWI 
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Figure 2. Initial imaging of contrast head MRI (a) 
MR spectroscopy, and (b) histopathological 
picture11 of case 1 supporting new case of GBM. 
 
Following surgery, the patient underwent 
radiochemotherapy 30 times in two months. She 
received a TMZ dose of 100 mg and 0.5 mg 
dexamethasone (DXM) orally once daily, 
simultaneously or concomitant with radiotherapy. 
Treatment was continued at 100 mg per day within 
7 days after concomitant therapy. Furthermore, 
TMZ and DXM were discontinued for 30 days. 
During this period, the patient’s clinical condition 
was good, and no new neurologic deficits were 
found on physical examination. The imaging test 
(MRI) following radiochemotherapy showed 
minimal contrast-enhanced lesions at the surgical 
bed in the left temporal lobe, suspected of residual 
tumor or the tumor was being recurrent. 
Therapy was continued with 1x200 mg adjuvant 
TMZ for six cycles, beginning four months after 
surgery. Each cycle comprised 5 days of TMZ 
treatment followed by a 23-day resting phase. On 
the second cycle, MRI showed minimal contrast-
enhanced lesions at the surgical bed in the left 
temporal lobe, suspected of being recurrent or 
residual post-surgical gliosis in the left temporal 





Figure 3. Case 1 MRI imaging after 
radio-chemotherapy concomitant, (a) T1-weighted, 
(b) T2-weighted, and (c) DWI sequences. 
 
 
On the fifth cycle of adjuvant TMZ, no headaches, 
seizures, or other complaints except for nausea, a 
TMZ side effect, was reported by Mrs. N. Imaging 
test evaluation showed no recurrent mass at the 
surgical bed, only an encephalomalacia cyst in the 
left temporoparietal region. 
 
Figure 4. Comparison of contrast head MRI case 1 
after adjuvant TMZ in (a) the second and (b) the 
fifth cycle, (1) T1-weighted, (2) T2-weighted, and  
(3) DWI sequences. 
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 Her clinical condition at the last cycle was good, 
with no new neurologic deficits, and a complete 
response was considered (KPS 100). Imaging of the 
head with contrast CT scan was performed and 
showed no features indicative of recurrent mass at 
the surgical bed. 
 
Case 2 
A 41-year-old woman, Mrs. G, presented with a 
gradual onset of speech difficulty and progressive 
chronic headaches. There were no complaints of 
hemifacial spasms, hemiparesis, hemihypesthesia, 
seizures, decreased consciousness, vomiting, 
fevers, or history of head trauma. She had type 2 
diabetes mellitus as a comorbid disease, with 
routine insulin therapy. 
General examination revealed bradypsychia and 
bilateral papilledema. Laboratory test results were 
within normal limits. Initial imaging of the head 
with contrast MRI showed a mass with central 
cystic components and a hemorrhage in the left 
temporal lobe, 4.22x4.69x4.32 cm, accompanied 
by extensive tentacular edema surrounding the left 
lateral ventricle and ventricle III, causing a midline 
shift of 0.69 cm to the right. The magnetic 
resonance spectroscopy showed an increase in the 
choline to creatinine ratio, a decreased level of N-
acetyl aspartate (NAA), and increased lactate. 
Surgery was not performed because the patient 
refused it. A daily dose of 60 gray radiotherapy 
concomitant with 1x100 mg TMZ was administered 
for 42 days, starting one month after onset. The 
patient was discharged from the hospital with 
clinical improvement of KPS from a score of 60 to 
90. Imaging of the head with contrast MRI showed 
a contrast-enhanced mass with cystic components 
and hemorrhage in the left temporal lobe of 
3.8x2.4x3 cm; this was smaller than that seen in 
the previous MRI. 
Therapy was continued with 1x200 mg adjuvant 
TMZ for 7 cycles, starting 3 months after onset. 
Contrast MRI of the head following TMZ showed a 
contrast-enhanced mass of 4.32x3.5x2.35 cm in 
the left temporal lobe. The size was relatively the 
same compared to that seen in the previous MRI. 
Hence, TMZ was continued for up to 12 cycles. The 
patient had focal seizures in the 11th cycle, and 
clinical examination showed central-right facial 
and lingual palsy. The brain contrast MRI test after 
the entire TMZ cycle revealed a mass of 
5.29x4.2x3.37 cm with a necrotic area in the left 
temporal lobe, with surrounding edema. A larger 
tumor was found compared to the previous MRI, 
accompanied by displacement of the left lateral 
ventricle to the right. This condition supported a 
diagnosis of recurrent GBM. Tumor excision and 
craniotomy were conducted followed by 
radiochemotherapy and adjuvant TMZ. The 
histopathology test of tumor excision showed 
tissue with extensive necrosis and proliferation of 
round to oval, pleomorphic heavy nucleated 






Figure 5. Initial Contrast head MRI of case 2, (a) T1-
weighted, (b) T2-weighted, (c) DWI sequences, (d) 
MR spectroscopy, and  
(e) histopathological picture11 after surgery 
confirming GBM. 
 
Concomitant radiochemotherapy with 60 grays 
and 1x100 mg TMZ was conducted 18 months after 
onset. Contrast head MRI showed a GBM mass of 
3.6x3.3x4.3 cm; it was relatively more fixed than 
previously seen and accompanied by non-
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Figure 6. Case 2 contrast MRI after surgery and 
concomitant radio-chemotherapy, (a) T1-weighted, 
(b) T2-weighted, (c) and DWI sequences. 
 
After a month, adjuvant TMZ with 1x200 mg TMZ 
was administered for 5 days, with a 23-day resting 
phase. The dosage of DXM was tapered after two 
weeks in each cycle of therapy. The imaging test 
on the second cycle showed an intra-axial mass in 
the left temporal horn with a necrotic area and 
extensive perifocal edema resulting in a 1.4-cm 
midline shift to the right. The patient was found to 
have several neurologic deficits during these 
periods but improved clinically with steroid 
administration and rehabilitation therapy. The 
brain contrast MRI after the fifth cycle showed an 
intra-axial mass in the cortical and subcortical 
regions of the left temporal lobe of 5x4,4x5,4 cm 
with a necrotic area and perifocal edema pressing 
on the left lateral ventricle. The size of the mass 
was larger in comparison to that shown by the 
previous MRI. The patient’s clinical condition 
became progressively worse, and she died 26 
months after being diagnosed with GBM. 
 
Discussion 
Both case reports showed GBM in women in their 
reproductive age, and 1.5 times more frequent in 
men than in women, and twice as frequent in 
people with lighter skin coloring.9 Weingart et al. 
also found a greater prevalence of case data in 
men than in women, approximately 1.6:1.0, and 
that onset was more likely to appear during the 
sixth decade. Although GBM has rarely been found 
in African Americans, there is no significant 
difference in the incidence of GBM cases after 
adjusting for race and age.10 
 
 
Figure 7. Comparison of contrast head MRI case 2 
after repeated adjuvant TMZ in (a) the second and  
(b) the fifth cycle, (1) T1-weighted, (2) T2-
weighted, and (3) DWI sequences. 
 
 
Clinical symptoms of GBM can be either specific or 
nonspecific. Case 1 shows a nonspecific major 
complaint of gradually increasing severe left-side 
headaches, whereas case 2 shows gradually 
increasing severity of difficulty talking and 
progressive chronic headaches. Headaches occur in 
about 77% of patients with GBM and comprise 
40% of early symptoms related to malignant 
gliomas. Its pattern is intermittent, sharp, and 
pressing, and they frequently occur in the morning, 
worsening as the day progresses and/ or with 
physical activity. Headache in the morning appears 
as a result of hypercapnia during sleep and ends in 
cerebral vasodilation and continued headache. The 
location of the headache is often difficult to 
determine, but pressure on the meninges structure 
of the headache area may indicate the location of 
the tumor.11 
Besides, both cases showed specific early 
symptoms. In the first case, a focal neurologic 
deficit of the central-right facial and lingual paresis 
and mild right hemiparesis were found. In the 
second case, language disorder was found. These 
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 specific symptoms may indicate the location of 
lesions or may be a consequence of the effect of 
the mass. In 42% of patients, hemiparesis was 
noted, while 14% showed hemianesthesia.10 
Lesions are often located in the cerebral 
hemispheres and rarely in the posterior fossa and 
brainstem.11 
The rapid development of neuroradiology has 
made it easier for practitioners to find new cases 
of GBM and evaluate therapy. In terms of the 
radiological location of the tumor, both cases 
presented in the present study show the same 
location in the left temporal lobe. Specific and 
nonspecific clinical symptoms can include the 
effects of a tumor mass on surrounding brain 
parenchyma. In a study by Tanaka et al. (2013) of 
105 patients with GBM, 60 patients or 57% had a 
characteristic tumor site in the temporal lobe.2 
Both cases showed classic features of GBM on 
imaging of contrast head MRI. A T1-weighted 
sequence showed an intra-axial mass tumor with a 
contrast-enhanced ring and a central necrotic area. 
A contrast-enhanced ring border is indicative of an 
active tumor. The features of T2-weighted MRI in 
both cases also revealed a hyperintense area 
around the lesions called perilesional edema, 
which indicates infiltrative tumors. The second 
case showed more heterogeneous mass features 
and intratumoral bleeding. The DW1 sequences 
showed a non-restricted diffusion area. These 
three sequences strongly support the existence of 
a GBM, adjusted to clinical conditions. 
Spectroscopic MR revealed increased choline and 
creatinine as well as lactate but a relative decrease 
in NAA. These features correspond to high-grade 
glioma neoplasms. A ratio of twice as much choline 
as creatinine strongly supports the presence of a 
high-grade glioma.14 
The initial standard management for GBM is 
surgery, followed by concomitant 
radiochemotherapy and adjuvant TMZ therapy. In 
case 1, surgery was performed immediately after 
head MRI, whereas case 2 involved concomitant 
radiochemotherapy due to the patient’s refusal of 
surgery. Surgery in case 2 was performed when 
new neurologic deficits were found in the only 
adjuvant TMZ based on MRI, which showed an 
increased size in tumor mass and extension of 
perilesional edema, reflecting a recurrence of 
GBM. Adjuvant TMZ therapy was performed after 
concomitant radiochemotherapy in both cases. In 
case 1, the patient received adjuvant TMZ for 6 
cycles after concomitant radiochemotherapy with 
prior surgery. In case 2, the patient received 
adjuvant TMZ twice; the first adjuvant TMZ was 
performed after concomitant radiochemotherapy 
without prior surgery, while the second was 
performed following standard management, i.e. 
after concomitant radiochemotherapy with prior 
surgery. The timing for the adjuvant TMZ therapy 
was also different; the first was for 12 cycles and 
the second for 5 cycles. Adding adjuvant TMZ after 
radiochemotherapy is clinically and statistically 
significant and provides a survival benefit with 
minimal toxicity.4 Optimal dosage and usage 
duration of TMZ are still subjects of debate.5  
The evaluation of adjuvant TMZ in GBM is highly 
significant. Several criteria were examined in this 
evaluation.11 A study by Chinot et al. applied the 
RANO criteria to evaluate the TMZ response in 
GBM. The evaluations included complete response, 
partial response, stable disease, and progression. 
Imaging of contrast T1, contrast T2/FLAIR, or DWI 
sequence; patient’s clinical condition and use of 
steroids form the basis of a TMZ response. It is 
recommended that the RANO criteria be applied 
within 12 weeks after radiochemotherapy. Based 
on the RANO Working Group, these criteria also be 
applied post-surgery, radiosurgery, and 
immunotherapy.7  
The TMZ response after radiochemotherapy is 
analyzed by comparing the differences in the MRI 
features of the early and final cycles of the 
adjuvant TMZ. Steroid use and clinical condition 
are also analyzed in the RANO criteria. We 
assessed the adjuvant TMZ response after the 
patient received concomitant radiochemotherapy 
and surgery. The first case involved 6 cycles of 
adjuvant TMZ. The patient complained only of 
nausea as a side effect of TMZ and was not given 
until the last cycle. These three criteria – radiologic 
features no existence of contrast enhancement 
and new lesions, good clinical conditions, and no 
steroid use – are included in the complete 
response according to the RANO criteria. 
The patient underwent two adjuvant TMZ 
treatments in the second case. The second 
adjuvant TMZ was performed after surgery and 
radiochemotherapy, with DXM for two weeks in 
each cycle of adjuvant TMZ. Although the steroid 
dosage was increased, the patient’s clinical 
condition continued to worsen. In consideration of 
the clear severity of a patient’s clinical condition, 
even if the steroid dosage was increased and a 
significantly increasing lesion size was noted based 
on MRI, the TMZ response included in the 
progression criteria shows recurrence. Postponing 
surgery as initial therapy of standard GBM 
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management has the potential to decrease overall 
survival time.  
The patient in case 2 also suffered from type 2 
diabetes mellitus. In a retrospective cohort study 
by Chambless et al. (2012) of 171 patients with 
high- grade gliomas, 15 patients (8.8%) had a 
history of diabetes mellitus type 2. In these 
patients, there was a decrease in median overall 
survival (312 and 470 days, p=0.003) and 
Progressive Free Survival (PFS) (106 and 166 days, 
p=0.04) compared to non-diabetic patients.12 Early 
MRI in case 2 showed intratumoral bleeding and 
extensive perifocal edema, describing the 
infiltrative characteristic of the tumor. There may 
also have been TMZ resistance. A review article by 
Lee (2016) found that 50% of GBM patients 
treated with TMZ failed to respond to it.13 In a 
review, Repeated resections are considered for 
progressive or recurrent GBM to improve the 
patient’s life expectancy and to confirm the 
diagnosis, primarily histologically. The average 
survival time is 14 weeks.14 
In both cases, the prognostic factors differentiating 
adjuvant TMZ response after concomitant 
radiochemotherapy and surgery according to the 
RANO criteria are as follows: the presence of 
comorbidity, intratumoral bleeding shown on MRI 
before diagnosis, and surgery as the initial 
standard treatment for GBM management. Several 
studies investigated the effectiveness of TMZ in 
standard GBM management. A study by Jeon 
(2009) of 79 new GBM cases in patients with a 
median age of 52 years provided primary overall 
survival output data. The median overall survival 
time was 18.3 months (95% CI; 16.3–20.1 months), 
and the rate of progression was 6.7 months (95% 
CI; 5.2–8.3 months). Survival rates for year 1 and 
year 2 were 70.1% and 37.1%, respectively. More 
than 80 patients with KPS after operation show 
survival rate longer compared to patients with KPS 
values lower than 80 (23.1 months compared to 
13.4 months, p<0.001).15 A study by Lee (2012) 
demonstrated that radiochemotherapy and 
adjuvant TMZ in older patients with GBM resulted 
in longer survival rates. Management of 
radiochemotherapy and adjuvant TMZ 
administered to 70 patients older than 70 years 
diagnosed with GBM was examined. The median 
overall survival time was 11.8 months (95%CI; 8.7–
14.8). Based on multivariate analysis, total tumor 
excision is significantly related to longer overall 
survival time (hazard ratio [HR]=0;236; 95% CI; 
0.060–0.922; p=0.038) and good functional status 
(HR=0.124; 95% CI; 0.022–0.693; p=0.017).16 In 
another study, 25 adult patients with a median age 
of 53 years diagnosed with GBM and with KPS 
scores higher than 70 were prospectively studied 
with a median follow-up of 12.4 months. All 
patients underwent radiochemotherapy, and 19 
patients (76.0%) underwent adjuvant TMZ. The 
median overall survival time was 15.67 months 
(95% CI; 11.56–20.04). The delay of radiotherapy 
up to more than 6 weeks following surgery is an 
independent prognostic factor related to reduced 
overall survival time (4.0 compared to 16.1 
months; p=0.027).17 
The Karnofsky Performance Status scale is a 
general measurement to determine the prognosis 
of GBM based on the clinical condition. Several 
factors were related to increased survival time of 
GBM patients; these included higher KPS values 
post-surgery (p=0.0001), radiation therapy 
(p<0.0001), younger age (p=0.0443), and the non-
existence of diabetes (p=0.0006).18 
Furthermore, age is an important factor in GBM 
prognosis. Older age at onset is reported to be a 
significantly disadvantageous prognostic factor for 
GBM. Non-aggressive treatment is considered for 
older GBM patients, such as biopsy or palliative 
care due to the potential for intolerance to 
standard therapies.2 The percentage of patients 
less than 40 years old with a survival rate within 5 
years for 34% compared to only 65% of those aged 
years 40 or older. The age of 40 years is the 
threshold in the group division of patients with 
GBM related to disease prognosis.19 A study by 
Darefsky et al. (2012) 
showed that a group of 20–44 years old with GBM 
had a survival time of five years. In the cases 
diagnosed with GBM in this age group, the survival 
rate is 5 years in 12% (95% CI, 9%–16%) in 1993–
1995 and 16% (95% CI, 13%–20%) in 2002–2004. In 
GBM patients in this group who underwent surgery 
and radiotherapy, the survival rate in five years is 
14% (95% CI, 10%–20%) in cases diagnosed from 
1993–1995 and 19% (95% CI, 15%-23%).20 
 
Conclusion 
Prognostic factors that differentiate TMZ response 
in both cases were the presence of comorbidity, 
intratumoral hemorrhage seen on MRI, and 
surgery performed early in the diagnosis. Based on 
the RANO criteria and prognostic factors that 
support a TMZ response, the role of adjuvant TMZ 
can be said to be important in the standard 
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